Asgard Therapeutics

Asgard Therapeutics

Forskning inom bioteknik

Lund, Sköna 6 517 följare

Swedish biotech company exploring reprogramming as the next leap forward in cancer immunotherapy

Om oss

Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biological properties of professional antigen presenting cells. Backed by Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden, Asgard Therapeutics aims to build a pipeline of personalized cancer immunotherapies optimized to each unique patient.

Bransch
Forskning inom bioteknik
Företagsstorlek
2–10 anställda
Huvudkontor
Lund, Sköna
Typ
Publikt aktiebolag
Grundat
2018
Specialistområden
Cell Reprogramming, Cancer Immunotherapy och Dendritic cells

Adresser

Anställda på Asgard Therapeutics

Uppdateringar

Liknande sidor

Finansiering

Asgard Therapeutics 3 rundor totalt

Senaste finansieringsrunda

Serie A

32 648 548,00 US$

Se mer info på crunchbase